Meeting
2022 ASCO Genitourinary Cancers Symposium
CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma.
Authors
Huihui Ye
UCLA David Geffen School of Medicine, Los Angeles, CA
Huihui Ye , Rong Rong Huang , Brian M. Shuch , Zhengshan Chen , Jonathan W. Said , Allan J. Pantuck , Siler Panowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 384)
DOI
10.1200/JCO.2022.40.6_suppl.384
Abstract #
384
Poster Bd #
J3
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Malignant ascites as a manifestation of advanced papillary renal cell cancer (pRCC).
First Author: Julia C. Friend
Poster
2013 Genitourinary Cancers Symposium
SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma.
First Author: John A. Thompson
Poster
2024 ASCO Genitourinary Cancers Symposium
Fluorescence in situ hybridization utility in the care management of renal cell carcinoma (prospective study, 30 cases).
First Author: Rafik BEN Tayeb
Poster
2023 ASCO Genitourinary Cancers Symposium
Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.
First Author: Chris Labaki